Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer in Switzerland. Despite intensive chemotherapy, one fifth of the patients suffer a relapse, which usually goes hand in hand with a poor prognosis. Researchers from the University of Zurich and the Children’s Hospital Zurich have now found a way to kill off resistant leukemia cells: via necroptosis.
ALL stems from malignant transformed precursor lymphocytes, the blood’s defense cells. Nowadays, four out of five young leukemia patients can be treated successfully with aggressive chemotherapy.
However, this ostensibly positive record in pediatric oncology is tarnished by the fact that the cancer cells develop a resistance to the drugs in around 20 percent of cases. As their chances of recovery are slim, medicine is urgently seeking new treatment options for these patients.
Chemotherapeutic drugs trigger a program of molecular “suicide” – so-called “apoptosis” – in the cancer cells. All the cells in our body possess this mechanism, which is activated as soon as a cell is severely damaged. Every day, millions of cells die naturally from apoptotic processes – which is crucial for our bodies to function normally. However, cancer cells have founds ways and means to upset the balance between survival and death.
Despite aggressive chemotherapy, they manage to suppress apoptosis, which renders them resistant to the drugs. A team of scientists headed by UZH researchers Jean-Pierre Bourquin and Beat Bornhauser from the Children’s Hospital Zurich has now found a way to eliminate these resistant leukemia cells.
Activation of necroptosis causes resistant cancer cells to die off
“Our research reveals that an alternative cell-death program, necroptosis, can be activated in human ALL cells. This enables leukemia cells that barely respond to existing chemotherapeutic drugs to be killed off,” explains Bornhauser, a researcher from the Department of Oncology.
The enzyme RIP1 kinase is chiefly responsible for regulating necroptosis. It controls the molecular switch points that govern whether the cell lives or dies. The researchers identified several substances known as “SMAC mimetics”, which activate RIP1 by suppressing the inhibition of the enzyme.
In order to test the efficacy of these SMAC mimetics, the group used a humanized mouse model they developed at the Children’s Hospital Zurich, which enables human leukemia cells to be studied in a living organism. This showed that the leukemia cells in one third of all patient samples tested responded highly sensitively to SMAC mimetics – and died off.
Molecular mechanism decoded with the aid of “gene scissors”
To find out how this cancer-inhibiting effect works, Scott McComb and Julia Aguadé-Gorgorio, the first authors of the study, used the CRISPR-Cas9 method, which is also referred to as “gene scissors”, for the first time in primary human leukemia cells. They discovered that both apoptosis and necroptosis, which are triggered by SMAC mimetics, specifically depend on RIP1 kinase.
None of the established chemotherapy drugs activates this RIP1-dependent cell-death mechanism. If the genes responsible for apoptosis were disabled via genome editing, the leukemia cells died due to necroptosis after SMAC mimetics had been administered. If the necroptotic genes were no longer functioning properly, apoptosis led to cell death. Only the simultaneous deactivation of apoptotic and necroptotic genes resulted in the complete resistance of the cancer cells to SMAC mimetics.
Therefore, the simultaneous activation of apoptosis and necroptosis in the cancer cells is responsible for the strong anti-leukemic effect. “SMAC mimetics have great potential to eliminate leukemia cells in patients that aren’t sensitive to established chemotherapeutic drugs. They are effectively a double-edged sword: They kill cells that block apoptosis through necroptosis,” concludes Bornhauser. The researchers are now looking for suitable biomarkers to identify patients who might benefit from treatment with SMAC mimetics in clinical trials.
The project was funded by the Childhood Cancer Research Foundation Switzerland, the Empiris Foundation, the Panacée Foundation, the Swiss Cancer Research Foundation, the Clinical Research Priority Program “Human Hemato-Lymphatic Diseases“ and the University of Zurich’s Forschungskredit and the Children’s Research Center at the Children’s Hospital Zurich.
Scott McCom, Júlia Aguadé-Gorgorió, Lena Harder, Blerim Marovca, Gunnar Cario, Cornelia Eckert, Martin Schrappe, Martin Stanulla, Arend von Stackelberg, Jean-Pierre Bourquin, Beat C. Bornhauser. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Science Translational Medicine. May 18, 2016. doi: 10.1126/scitranslmed.aad2986
Beat Bornhauser, PhD
Department of Oncology, Children’s Research Center
Children’s Hospital Zurich
Phone: +41 44 634 88 17
Kurt Bodenmüller | Universität Zürich
Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University
Direct conversion of non-neuronal cells into nerve cells
03.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.
Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
13.07.2018 | Event News
13.07.2018 | Materials Sciences
13.07.2018 | Life Sciences